Ubicación: Global + English
Global Global Algérie Français Algeria English Angola Português Angola English Argentina Español Argentina English Australia English Austria Deutsch Austria English Azerbaijan English Azerbaijan Русский Bahrain English Bangladesh English Belgium English Belgium Français Belgium Nederlands Brazil Português Brazil English Bulgaria български Bulgaria English Cameroon English Cameroon Français Canada English Canada Français Chile Español Chile English China 中文 China 日本語 China English Colombia Español Colombia English Croatia English Czech Republic Čeština Czech Republic English Denmark English Djibouti English Ecuador Español Ecuador English Egypt English Estonia English Ethiopia English Finland Suomi Finland English France Français France English Georgia English Georgia Русский Germany Deutsch Germany English Ghana English Greece Ελληνικά Greece English Guatemala Español Guatemala English Hong Kong, China English Hong Kong, China 中文 Hungary Magyar Hungary English India English Indonesia English Iraq English Ireland English Italy Italiano Italy English Ivory Coast Français Ivory Coast English Japan 日本語 Japan English Jordan English Kazakhstan Русский Kazakhstan English Kenya English Kuwait English Kyrgyzstan Русский Kyrgyzstan English Latvia English Lithuania English Malaysia English Mauritius English Mauritius français (Maurice) Mexico Español Mexico English Moldova Română Moldova English Mongolia English Morocco English Morocco Français Mozambique Português Mozambique English Netherlands Nederlands Netherlands English New Zealand English Nigeria English Norway English Oman English Pakistan English Paraguay Español Paraguay English Peru Español Peru English Philippines English Poland Polski Poland English Portugal Português Portugal English Qatar English Republic of Korea 한국어 Republic of Korea English Romania Română Romania English Saudi Arabia English Serbia Српски Serbia English Singapore English Slovakia English Slovenia English South Africa English Spain English Spain Español Sri Lanka English Sweden English Switzerland Deutsch Switzerland Français Switzerland Italiano Switzerland English Tanzania English Thailand ไทย Thailand English Togo English Togo Français Tunisia English Tunisia Français Türkiye Türkçe Türkiye English Turkmenistan Русский Turkmenistan English Ukraine Українська Ukraine English United Arab Emirates English United Kingdom English Uruguay Español Uruguay English USA English Uzbekistan English Uzbekistan Русский Vietnam Tiếng Việt Vietnam English

Nipple fissure, or cracked nipple, is one of the most common and painful complications of lactation, and reproducible experimental models are essential for evaluating the safety and efficacy of nipple care products before human use. This article describes standardized methods for constructing nipple fissure models in lactating rodents, covering model induction techniques, key testing items, evaluation endpoints, and practical applications in product development and regulatory documentation.

Technical Overview

Nipple fissure is characterized by disruption of the nipple and areolar epidermis, typically caused by repetitive mechanical friction during breastfeeding, combined with moisture, maceration, and local inflammation. To evaluate healing creams, barrier products, hydrogel dressings, and other topical interventions, preclinical studies require an animal model that faithfully reproduces the epidermal damage, inflammatory response, and repair dynamics of human nipple fissures.

The most widely accepted approach uses lactating Sprague-Dawley or Wistar rats, in which a standardized epidermal defect is created on the nipple surface through controlled mechanical abrasion or superficial incision. The resulting wound mimics the clinical features of nipple fissure, including epidermal loss, crusting, erythema, and delayed re-epithelialization. Study protocols are designed in accordance with the principles of ISO 10993-1 for biological evaluation of medical devices, ISO 10993-23 for irritation testing where applicable, OECD Good Laboratory Practice principles, and applicable national laboratory animal care standards such as the GB/T 16886 series adopted in China. All procedures are reviewed and approved by an Institutional Animal Care and Use Committee (IACUC) and are typically conducted in accredited third-party laboratories or GLP-compliant facilities.

Testing Samples

Test Articles

Typical test articles submitted for evaluation in nipple fissure models include:

  • Lanolin-based or petrolatum-based nipple creams and balms intended for breastfeeding mothers
  • Hydrogel and foam wound dressings for nipple care
  • Barrier films and protective coatings forming an occlusive or semi-occlusive layer
  • Wound-healing ointments containing active pharmaceutical or botanical ingredients
  • Medical-grade silicone gels and moisturizing formulations
  • Comparative reference products, such as marketed over-the-counter nipple care preparations, used as positive controls

Model Animals

The standard model uses healthy adult female Sprague-Dawley rats on postpartum days 3 to 7, during the peak lactation period when nipples are enlarged, traumatized by suckling, and physiologically comparable to the human lactating condition. New Zealand white rabbits may be used as an alternative species when a larger test surface or additional sampling is required. Animals are acclimatized for at least 3 to 7 days before the study, housed under controlled conditions of 20 to 26 degrees Celsius, 40 to 70 percent relative humidity, and a 12-hour light-dark cycle, with suckling pups maintained with the dams to preserve the lactating state.

Testing Items

A comprehensive nipple fissure model study typically evaluates the following items:

  • Model validation parameters: macroscopic wound morphology, epidermal defect uniformity, crust formation, and erythema scoring immediately after induction
  • Wound healing rate and wound area reduction kinetics measured by calibrated image analysis
  • Re-epithelialization index and time to complete epidermal coverage
  • Histopathological examination using hematoxylin-eosin and Masson trichrome staining, including epidermal thickness, inflammatory cell infiltration, and collagen deposition scoring
  • Inflammatory cytokine quantification, including IL-1 beta, IL-6, and TNF-alpha, by enzyme-linked immunosorbent assay (ELISA)
  • Expression of repair-related growth factors such as epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF)
  • Skin barrier recovery assessment, including transepidermal water loss (TEWL) and skin surface pH
  • General clinical observations, body weight, pup weight gain as an indirect welfare indicator, and local tolerance at the application site

Testing Methods

Model Induction

Animals are anesthetized by intraperitoneal injection of an approved anesthetic or by inhalation anesthesia, and the ventral mammary region is gently depilated. A standardized fissure lesion is then created on the selected nipples using one of the following validated methods:

  • Mechanical abrasion method: the nipple tip and surrounding epidermis are abraded with sterile fine-grit sandpaper or a sterile surgical blade in a controlled, repeatable manner until a uniform superficial defect with pinpoint bleeding is achieved, without damaging the underlying dermis or mammary ducts
  • Scoring method: a defined criss-cross incision pattern of standardized depth is made on the nipple surface using a sterile scalpel, producing reproducible fissure-like clefts
  • Chemical irritation method: a defined irritant is applied repeatedly to the nipple surface under occlusion to induce epidermal erosion and inflammation, used primarily when an irritant-mediated pathology is required

Model success is confirmed immediately after induction by documenting consistent wound size, depth, and bleeding pattern. Animals with excessive, inconsistent, or full-thickness injury are excluded according to predefined criteria.

Grouping and Administration

Animals are randomly assigned to experimental groups, typically including an intact blank control, an untreated model control, a vehicle control, a positive control treated with a marketed reference product, and test article groups at low, medium, and high doses. A minimum of eight to ten valid nipples per group is recommended. The test article is applied topically to the fissured nipple, commonly twice daily for 5 to 7 consecutive days, with the application dose standardized per unit area. Suckling pups may be rotated or temporarily restricted to standardize the suckling trauma across groups and reduce variability.

Observation and Measurement

General condition, local skin reaction, and any signs of pain or distress are recorded daily. Nipple wounds are photographed with a calibrated scale on days 0, 1, 3, 5, and 7, and wound areas are quantified using image analysis software. The wound healing rate is calculated as the initial wound area minus the wound area at each time point, divided by the initial wound area, multiplied by one hundred percent.

Laboratory Analysis

At scheduled endpoints, nipple and periwound skin tissues are harvested, fixed in neutral buffered formalin, embedded in paraffin, sectioned, and stained for blinded histopathological scoring. Separate tissue samples are processed for ELISA, quantitative polymerase chain reaction, or Western blot analysis of inflammatory and repair biomarkers. Quantitative data are analyzed using appropriate statistical methods, typically one-way or repeated-measures analysis of variance, with statistical significance set at a probability value of less than 0.05.

Applications

Nipple fissure model studies serve multiple purposes across product development and regulatory pathways:

  • Efficacy substantiation for nipple care creams, balms, and dressings marketed to breastfeeding women, supporting claims such as accelerated healing and relief of discomfort
  • Comparative screening of candidate formulations, concentrations, and delivery vehicles during the research and development phase
  • Generation of preclinical efficacy and local safety data for product registration dossiers, claim verification files, and technical documentation for medical devices and cosmetic products
  • Support for ethical marketing claims that require objective laboratory evidence rather than consumer perception alone
  • Academic and mechanistic research into epidermal wound healing, lactation-associated skin injury, and topical anti-inflammatory interventions

FAQ

Which animal species are most suitable for nipple fissure model construction?

Lactating Sprague-Dawley or Wistar rats on postpartum days 3 to 7 are the preferred species because their nipples are enlarged, actively suckled, and physiologically comparable to the human lactating condition. Rabbits may be used when larger tissue samples or transdermal characterization is needed.

How is a successful model validated?

A successful model demonstrates uniform superficial epidermal loss with pinpoint bleeding, visible crusting and erythema within 24 hours, delayed spontaneous healing over the observation window, and histological confirmation of epidermal disruption with inflammatory infiltration but intact dermal structures.

What is the typical study duration?

A standard efficacy study runs 7 to 10 days from model induction, with daily application of the test article and endpoint evaluations on days 3, 5, and 7. Histopathological and biomarker analyses are typically completed within two to three weeks thereafter.

Which standards and guidelines apply to these studies?

Study design follows the biological evaluation principles of ISO 10993-1, with reference to ISO 10993-23 for irritation endpoints where relevant, OECD Good Laboratory Practice principles, and national laboratory animal standards such as the GB/T 16886 series. All protocols require IACUC approval.

Can these studies be outsourced?

Yes. Nipple fissure model studies are routinely conducted by accredited third-party laboratories and GLP-compliant preclinical research institutions that hold the necessary animal facility licenses and ethical approvals, ensuring data quality and regulatory acceptability.